Abstract
The α7 nicotinic acetylcholine receptors (nAChRs), ligand-gated Ca2+ channels composed of homopentamers of α7 subunits, represent the most abundant with α4β2 nAChRs in the brain. Several lines of evidence suggest that α7 nAChRs play a role in the physiology of neuropsychiatric diseases such as schizophrenia, Alzheimer's disease, anxiety, depression, and drug addiction; hence, α7 nAChRs seem to be attractive therapeutic targets for these diseases. Several researchers have attempted to develop radioligands that can be used to selectively and quantitatively examine the distribution of α7 nAChRs in the human brain with positron emission tomography (PET) or single photon emission tomography (SPECT). Although efforts are underway, very low density of α7 nAChR and scarcity of very high affinity ligands hamper the development of α7 subtype-selective radioligands for in vivo imaging. In this article, we review the recent topics on the development of PET/SPECT ligands for in vivo imaging of α7 nAChRs in the brain.
Keywords: nicotinic acetylcholine receptors, positron emission tomography (PET), single photon emission tomography (SPECT), schizophrenia, Alzheimer’s disease.
Current Topics in Medicinal Chemistry
Title:Recent Development of Radioligands for Imaging α7 Nicotinic Acetylcholine Receptors in the Brain
Volume: 10 Issue: 15
Author(s): Jun Toyohara, Jin Wu and Kenji Hashimoto
Affiliation:
Keywords: nicotinic acetylcholine receptors, positron emission tomography (PET), single photon emission tomography (SPECT), schizophrenia, Alzheimer’s disease.
Abstract: The α7 nicotinic acetylcholine receptors (nAChRs), ligand-gated Ca2+ channels composed of homopentamers of α7 subunits, represent the most abundant with α4β2 nAChRs in the brain. Several lines of evidence suggest that α7 nAChRs play a role in the physiology of neuropsychiatric diseases such as schizophrenia, Alzheimer's disease, anxiety, depression, and drug addiction; hence, α7 nAChRs seem to be attractive therapeutic targets for these diseases. Several researchers have attempted to develop radioligands that can be used to selectively and quantitatively examine the distribution of α7 nAChRs in the human brain with positron emission tomography (PET) or single photon emission tomography (SPECT). Although efforts are underway, very low density of α7 nAChR and scarcity of very high affinity ligands hamper the development of α7 subtype-selective radioligands for in vivo imaging. In this article, we review the recent topics on the development of PET/SPECT ligands for in vivo imaging of α7 nAChRs in the brain.
Export Options
About this article
Cite this article as:
Toyohara Jun, Wu Jin and Hashimoto Kenji, Recent Development of Radioligands for Imaging α7 Nicotinic Acetylcholine Receptors in the Brain, Current Topics in Medicinal Chemistry 2010; 10 (15) . https://dx.doi.org/10.2174/156802610793176828
DOI https://dx.doi.org/10.2174/156802610793176828 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy of Gene Therapy to Restore Cognition in Alzheimer’s Disease: A Systematic Review
Current Gene Therapy In Vitro Human Hepatocyte-Based Experimental Systems for the Evaluation of Human Drug Metabolism, Drug-Drug Interactions, and Drug Toxicity in Drug Development
Current Topics in Medicinal Chemistry Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety 5-HT1A Receptor, an Old Target for New Therapeutic Agents
Current Topics in Medicinal Chemistry Pneumonia in the Burn Patient
Current Respiratory Medicine Reviews Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases
Current Pharmaceutical Design Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach
Current Neuropharmacology Phage Display as a Tool for Protease Ligand Discovery
Current Pharmaceutical Biotechnology Astrocytic Adrenoceptors: A Major Drug Target in Neurological and Psychiatric Disorders?
Current Drug Targets - CNS & Neurological Disorders Working Memory in ADHD: Prefrontal/Parietal Connections
Current Drug Targets Molecular Mechanisms Involving Sigma-1 Receptor in Cell Apoptosis of BV-2 Microglial Cells Induced by Methamphetamine
CNS & Neurological Disorders - Drug Targets Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Stem Cell-Based Approaches for Intervertebral Disc Regeneration
Current Stem Cell Research & Therapy QSPR and Flow Cytometry Analysis (QSPR-FCA): Review and New Findings on Parallel Study of Multiple Interactions of Chemical Compounds with Immune Cellular and Molecular Targets
Current Drug Metabolism Co-Induction of CYP3A12 and 3A26 in Dog Liver Slices by Xenobiotics: Species Difference Between Human and Dog CYP3A Induction
Drug Metabolism Letters Asymmetric Syntheses Based on Organocatalysis
Mini-Reviews in Organic Chemistry Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry Translating Nucleic Acid Amplification Assays to the Microscale: Lab on a Chip for Point-of-Care Molecular Diagnostics
Current Analytical Chemistry